Nursing facility
Dignity Community Care
Dignity Community Care was paid $116.41M by Medicaid between Jan 2018 and Dec 2024, across 380 billing codes. Its largest line is 0450, Emergency room services — 31% of everything it billed.
33Billing provider infoDIGNITY COMMUNITY CARE
LOS ANGELES, CA 90015
LOS ANGELES, CA 90015
33aNPI1114081056assigned 12/21/2006
33bProvider typeSkilled Nursing Facility
28Total paid$116.41M
24GClaims1,988,758
24DCodes billed380
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Skilled Nursing Facility providers in California
Rank by total paid#2 of 547
Median peer was paid$73K
This provider vs. median1,589×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 332,451 | $25.10M | |
| 2019 | 303,813 | $27.39M | |
| 2020 | 239,449 | $12.91M | |
| 2021 | 261,834 | $12.93M | |
| 2022 | 279,365 | $13.53M | |
| 2023 | 308,138 | $13.81M | |
| 2024incomplete | 263,708 | $10.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 31% | 169,111 | 149,491 | $36.40M |
| 0250 | 13% | 96,333 | 50,257 | $15.68M | |
| J3490 | Unclassified drugs | 6.6% | 93,407 | 49,650 | $7.70M |
| 80053 | Comprehensive metabolic panel | 5.0% | 89,063 | 80,648 | $5.86M |
| 36415 | Collection of venous blood by venipuncture | 3.5% | 18,410 | 16,389 | $4.12M |
| 86850 | 1.7% | 11,990 | 11,279 | $1.99M | |
| 71045 | Radiologic examination, chest; single view | 1.7% | 50,827 | 48,361 | $1.98M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 11,537 | 11,192 | $1.89M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 12,395 | 12,022 | $1.89M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 25,207 | 21,101 | $1.55M |
| 82962 | 1.2% | 31,394 | 26,256 | $1.41M | |
| Z7502 | 1.2% | 35,510 | 34,965 | $1.36M |
368 more codes
| 59025 | Fetal non-stress test | 1.0% | 21,935 | $1.20M |
| 0301 | <1% | 8,452 | $1.16M | |
| 99283 | Emergency room visit (moderate) | <1% | 9,941 | $1.02M |
| 81001 | <1% | 55,670 | $892K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 9,587 | $865K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 32,028 | $854K |
| 99284 | Emergency room visit (serious) | <1% | 9,149 | $840K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 8,272 | $807K |
| 0360 | <1% | 9,338 | $805K | |
| 0710 | <1% | 13,038 | $729K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 51,118 | $666K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 7,529 | $662K |
| 99285 | Emergency room visit (most serious) | <1% | 4,506 | $654K |
| 76801 | <1% | 5,088 | $612K | |
| A9150 | Non-prescription drugs | <1% | 5,651 | $598K |
| 76830 | Ultrasound, transvaginal | <1% | 5,766 | $551K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,051 | $538K |
| Z9725 | <1% | 12,270 | $528K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,369 | $504K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,111 | $492K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13,412 | $477K |
| 99199 | Unlisted special service, procedure or report | <1% | 7,134 | $476K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 84,273 | $436K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,955 | $434K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,529 | $424K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,404 | $417K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,044 | $412K |
| 73564 | <1% | 5,516 | $402K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,970 | $399K |
| 0949 | <1% | 16,675 | $375K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,853 | $354K |
| 84484 | <1% | 30,248 | $351K | |
| 73130 | <1% | 4,689 | $344K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 6,289 | $320K |
| 0750 | <1% | 5,225 | $314K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,813 | $300K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,840 | $288K |
| 83880 | <1% | 22,239 | $275K | |
| 99221 | <1% | 12,177 | $271K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,403 | $271K |
| 73610 | <1% | 3,916 | $271K | |
| 93971 | <1% | 2,311 | $261K | |
| 73030 | <1% | 4,026 | $261K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,936 | $256K |
| 81025 | <1% | 8,925 | $256K | |
| 0720 | <1% | 6,897 | $249K | |
| 83690 | <1% | 52,651 | $242K | |
| 86803 | <1% | 23,598 | $234K | |
| 70486 | <1% | 2,290 | $227K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,906 | $225K |
| 73630 | <1% | 4,552 | $224K | |
| 73110 | <1% | 2,651 | $222K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,847 | $219K |
| 0121 | <1% | 1,070 | $217K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,817 | $212K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,444 | $211K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,229 | $204K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 3,182 | $200K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,743 | $187K |
| 76641 | <1% | 3,993 | $184K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,840 | $180K |
| 72110 | <1% | 1,461 | $175K | |
| 0272 | <1% | 6,511 | $161K | |
| 87040 | <1% | 5,329 | $156K | |
| 87081 | <1% | 3,194 | $150K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,934 | $149K |
| 0214 | <1% | 1,359 | $142K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,270 | $137K |
| 0762 | <1% | 2,565 | $136K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,446 | $128K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,560 | $128K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,839 | $126K |
| 93017 | <1% | 2,608 | $124K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,259 | $123K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 38,631 | $112K |
| 76870 | <1% | 982 | $111K | |
| 73140 | <1% | 1,051 | $111K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,645 | $108K |
| 90715 | <1% | 5,166 | $108K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,137 | $107K |
| 73080 | <1% | 1,715 | $106K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,914 | $104K |
| 73590 | <1% | 2,127 | $103K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,422 | $103K |
| 81003 | <1% | 12,718 | $101K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 3,526 | $101K |
| 86592 | <1% | 2,257 | $98K | |
| 84702 | <1% | 7,324 | $97K | |
| 86703 | <1% | 9,991 | $92K | |
| 0270 | <1% | 25,559 | $90K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,452 | $87K |
| 77065 | Tomosynthesis, mammo | <1% | 1,681 | $86K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,122 | $85K |
| 85730 | <1% | 22,854 | $79K | |
| 87210 | <1% | 4,545 | $77K | |
| 73090 | <1% | 1,629 | $77K | |
| 86901 | <1% | 12,319 | $75K | |
| 85610 | <1% | 24,420 | $74K | |
| 12011 | <1% | 444 | $74K | |
| 87420 | <1% | 582 | $73K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,204 | $72K |
| 73502 | <1% | 1,304 | $72K | |
| 87077 | <1% | 3,426 | $72K | |
| 0682 | <1% | 201 | $71K | |
| 86900 | <1% | 12,287 | $70K | |
| 88304 | <1% | 1,473 | $69K | |
| 72131 | <1% | 531 | $68K | |
| 52000 | <1% | 635 | $68K | |
| 10060 | <1% | 735 | $64K | |
| 0160 | <1% | 935 | $60K | |
| 71101 | <1% | 706 | $59K | |
| 72100 | <1% | 497 | $59K | |
| 87631 | <1% | 938 | $58K | |
| 85027 | <1% | 14,574 | $58K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 192 | $56K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 461 | $55K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,161 | $54K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 398 | $53K |
| J1815 | Injection, insulin, per 5 units | <1% | 2,165 | $53K |
| Z7610 | <1% | 10,295 | $53K | |
| 12001 | <1% | 679 | $53K | |
| 87070 | <1% | 1,099 | $52K | |
| 93458 | <1% | 70 | $50K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,399 | $44K |
| 0761 | <1% | 1,978 | $41K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 2,336 | $41K |
| 87186 | <1% | 2,589 | $39K | |
| 80047 | <1% | 345 | $39K | |
| 51741 | <1% | 2,513 | $38K | |
| 83605 | <1% | 5,634 | $36K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,560 | $36K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,053 | $36K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,847 | $35K |
| 85007 | <1% | 12,105 | $33K | |
| 12002 | <1% | 484 | $33K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 454 | $33K |
| 70496 | <1% | 295 | $33K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,162 | $32K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 160 | $32K |
| A9270 | Non-covered item or service | <1% | 7,007 | $31K |
| 99152 | <1% | 1,116 | $29K | |
| 0760 | <1% | 1,275 | $28K | |
| 0370 | <1% | 6,688 | $27K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,564 | $27K |
| 73620 | <1% | 234 | $26K | |
| 51729 | <1% | 753 | $26K | |
| 73560 | <1% | 316 | $25K | |
| 29125 | <1% | 638 | $24K | |
| 73120 | <1% | 255 | $24K | |
| 72170 | <1% | 1,264 | $23K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,796 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 560 | $22K |
| 86759 | <1% | 1,659 | $22K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,353 | $22K |
| 74018 | <1% | 172 | $20K | |
| 70491 | <1% | 138 | $20K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 358 | $20K |
| 70498 | <1% | 311 | $20K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,686 | $19K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,242 | $18K |
| 82803 | <1% | 1,384 | $17K | |
| 0122 | <1% | 77 | $17K | |
| 87522 | Neg quan hep c or qual rna | <1% | 974 | $17K |
| 84145 | <1% | 1,873 | $17K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,946 | $17K |
| 88312 | <1% | 4,129 | $17K | |
| 93970 | <1% | 114 | $17K | |
| 71250 | <1% | 122 | $17K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,261 | $16K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,434 | $16K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,906 | $16K |
| 29515 | <1% | 314 | $15K | |
| 73660 | <1% | 93 | $15K | |
| 84703 | <1% | 1,820 | $15K | |
| G0378 | Hospital observation service, per hour | <1% | 290 | $14K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 8,225 | $14K |
| 83735 | <1% | 4,534 | $14K | |
| 76376 | <1% | 553 | $14K | |
| 72040 | <1% | 141 | $13K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 945 | $12K |
| E0601 | Continuous positive airway pressure (cpap) device | <1% | 233 | $12K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 27 | $12K |
| 77014 | <1% | 194 | $12K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 383 | $12K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,309 | $11K |
| 80074 | <1% | 29 | $11K | |
| 51797 | <1% | 693 | $11K | |
| 82375 | <1% | 1,308 | $10K | |
| 73552 | <1% | 326 | $9K | |
| 83615 | <1% | 1,008 | $9K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 45 | $9K |
| A4649 | Surgical supply; miscellaneous | <1% | 22,983 | $9K |
| 96376 | <1% | 2,120 | $9K | |
| 82570 | <1% | 475 | $9K | |
| 97750 | <1% | 610 | $9K | |
| 80061 | Lipid panel | <1% | 1,277 | $8K |
| 84133 | <1% | 449 | $8K | |
| 85384 | <1% | 307 | $8K | |
| 76770 | <1% | 25 | $8K | |
| 51784 | <1% | 443 | $8K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 2,732 | $8K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 54 | $7K |
| 85380 | <1% | 1,851 | $7K | |
| E1390 | Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate | <1% | 163 | $7K |
| 73060 | <1% | 301 | $7K | |
| 72072 | <1% | 52 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,325 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,783 | $6K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 936 | $6K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 348 | $6K |
| 74230 | <1% | 171 | $5K | |
| 77059 | <1% | 12 | $5K | |
| 81005 | <1% | 474 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,954 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,278 | $4K |
| 94060 | <1% | 73 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,676 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,409 | $4K |
| 77049 | <1% | 27 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,623 | $4K |
| 87147 | <1% | 1,031 | $4K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 221 | $4K |
| 86140 | <1% | 1,910 | $4K | |
| 73100 | <1% | 20 | $4K | |
| 83050 | <1% | 1,254 | $3K | |
| 93226 | <1% | 96 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,278 | $3K |
| 92522 | <1% | 56 | $3K | |
| T4541 | Incontinence product, disposable underpad, large, each | <1% | 100 | $3K |
| V5008 | Hearing screening | <1% | 191 | $3K |
| 47562 | <1% | 26 | $3K | |
| K0001 | Standard wheelchair | <1% | 78 | $3K |
| 94664 | <1% | 36 | $3K | |
| 84100 | <1% | 1,870 | $3K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 43 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 74 | $3K |
| E0562 | Humidifier, heated, used with positive airway pressure device | <1% | 215 | $3K |
| 87340 | <1% | 180 | $3K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 19 | $3K |
| 88313 | <1% | 323 | $3K | |
| 87088 | <1% | 881 | $3K | |
| 71010 | <1% | 210 | $3K | |
| 87205 | <1% | 822 | $3K | |
| 93976 | <1% | 40 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 704 | $3K |
| 76937 | <1% | 286 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,554 | $3K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,386 | $3K |
| 73600 | <1% | 72 | $3K | |
| Z7500 | <1% | 73 | $2K | |
| 94729 | <1% | 58 | $2K | |
| 76536 | <1% | 72 | $2K | |
| 82550 | <1% | 980 | $2K | |
| E0570 | Nebulizer, with compressor | <1% | 16 | $2K |
| E0443 | Portable oxygen contents, gaseous, 1 month's supply = 1 unit | <1% | 29 | $2K |
| 82009 | <1% | 449 | $2K | |
| C1769 | Guide wire | <1% | 291 | $2K |
| E0431 | Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing | <1% | 121 | $2K |
| 82731 | <1% | 15 | $2K | |
| 80185 | <1% | 116 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 622 | $2K |
| 82728 | <1% | 438 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,168 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 126 | $2K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 912 | $2K |
| 82553 | <1% | 391 | $2K | |
| 84132 | <1% | 1,048 | $2K | |
| 87451 | <1% | 55 | $2K | |
| 85651 | <1% | 971 | $2K | |
| 82248 | <1% | 16 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 84 | $2K |
| 0258 | <1% | 707 | $1K | |
| 84439 | <1% | 306 | $1K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 33 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 483 | $1K |
| E0143 | Walker, folding, wheeled, adjustable or fixed height | <1% | 12 | $1K |
| 88342 | <1% | 69 | $1K | |
| 0171 | Inj, epinephrine (belcher) | <1% | 174 | $1K |
| 94726 | <1% | 30 | $1K | |
| 85018 | <1% | 1,115 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 644 | $1K |
| 77001 | <1% | 56 | $1K | |
| 88307 | <1% | 156 | $1K | |
| 76942 | <1% | 25 | $1K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,033 | $1K |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 70 | $982.41 |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 13 | $963.60 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 99 | $937.86 |
| 99070 | <1% | 659 | $823.97 | |
| 0510 | <1% | 16 | $677.73 | |
| 76775 | <1% | 14 | $642.43 | |
| 0324 | <1% | 1,186 | $626.97 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 433 | $553.32 |
| 72128 | <1% | 12 | $549.83 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 102 | $488.04 |
| 0001A | <1% | 26 | $440.44 | |
| 97755 | <1% | 77 | $436.99 | |
| 84550 | <1% | 51 | $431.78 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 173 | $425.98 |
| 92611 | <1% | 26 | $414.84 | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 96 | $370.80 |
| V2632 | Posterior chamber intraocular lens | <1% | 41 | $300.60 |
| 0278 | <1% | 304 | $292.10 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 39 | $284.70 |
| 0402 | <1% | 636 | $254.36 | |
| 84112 | <1% | 28 | $244.85 | |
| 88329 | <1% | 17 | $232.81 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,168 | $227.41 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 188 | $224.75 |
| C9399 | Unclassified drugs or biologicals | <1% | 418 | $222.22 |
| 82330 | <1% | 26 | $219.70 | |
| 0420 | <1% | 1,211 | $201.55 | |
| 0430 | <1% | 564 | $189.05 | |
| 85014 | <1% | 339 | $177.99 | |
| 0440 | <1% | 83 | $174.00 | |
| 93247 | <1% | 110 | $167.65 | |
| 0320 | <1% | 360 | $165.92 | |
| 93246 | <1% | 15 | $140.30 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 75 | $127.73 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 33 | $102.58 |
| 0254 | <1% | 73 | $98.00 | |
| 99406 | <1% | 12 | $95.00 | |
| 19083 | <1% | 14 | $84.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 17 | $78.99 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 41 | $69.44 |
| 86920 | <1% | 12 | $66.31 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 49 | $63.75 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 12 | $61.38 |
| 99072 | <1% | 181 | $60.22 | |
| 99001 | <1% | 198 | $57.61 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $51.90 |
| 0305 | <1% | 2,976 | $50.61 | |
| 0730 | <1% | 981 | $49.60 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 126 | $42.42 |
| 97165 | <1% | 26 | $37.10 | |
| 76000 | <1% | 15 | $27.96 | |
| 88300 | <1% | 14 | $21.30 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 32 | $12.52 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $11.10 |
| 45388 | <1% | 13 | $10.00 | |
| 0302 | <1% | 1,253 | $9.13 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 15 | $6.84 |
| 0306 | <1% | 2,324 | $6.60 | |
| 0307 | <1% | 1,132 | $4.06 | |
| J7198 | Anti-inhibitor, per i.u. | <1% | 38 | $0.08 |
| 0351 | 0% | 257 | $0.00 | |
| 0489 | 0% | 612 | $0.00 | |
| 0300 | 0% | 978 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 141 | $0.00 |
| 0412 | 0% | 172 | $0.00 | |
| T5999 | Supply, not otherwise specified | 0% | 74 | $0.00 |
| A0425 | Ground mileage, per statute mile | 0% | 288 | $0.00 |
| 0361 | 0% | 204 | $0.00 | |
| 0340 | 0% | 40 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 12 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 15 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 16 | $0.00 |
| 0611 | 0% | 195 | $0.00 | |
| 0352 | 0% | 609 | $0.00 | |
| 0310 | 0% | 257 | $0.00 | |
| 0400 | 0% | 315 | $0.00 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 253 | $0.00 |
| 0341 | 0% | 52 | $0.00 | |
| 97166 | 0% | 12 | $0.00 | |
| 0610 | 0% | 57 | $0.00 | |
| 36561 | 0% | 18 | $0.00 | |
| 0410 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHENG, REBECCA (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY COMMUNITY CARE